---
title: "Sanofi raises guidance as new CEO looks to revamp drug pipeline"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294309315.md"
description: "The company now expects 2026 sales to grow by around 10% excluding currency changes, with business earnings per share rising slightly faster than sales."
datetime: "2026-07-30T06:04:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294309315.md)
  - [en](https://longbridge.com/en/news/294309315.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294309315.md)
---

# Sanofi raises guidance as new CEO looks to revamp drug pipeline

The company now expects 2026 sales to grow by around 10% excluding currency changes, with business earnings per share rising slightly faster than sales.

### Related Stocks

- [SNY.US](https://longbridge.com/en/quote/SNY.US.md)
- [SNYNF.US](https://longbridge.com/en/quote/SNYNF.US.md)

## Related News & Research

- [Sanofi raises sales outlook on Dupixent strength in boost for new CEO](https://longbridge.com/en/news/294305951.md)
- [Sanofi Says Weak Decision-Making Hurt Pipeline, Promises More Disciplined R&D](https://longbridge.com/en/news/294405008.md)
- [Sanofi Drops Dupixent Successor Candidate After Assessing Data](https://longbridge.com/en/news/293787328.md)
- [SAN: Q2 2026 saw strong sales and profit growth, led by Dupixent and new launches](https://longbridge.com/en/news/294334114.md)
- [Sanofi Expects Moderate Increases In R&D Spend](https://longbridge.com/en/news/294368088.md)